Novartis’ experimental cancer treatment wins endorsement of FDA advisers

The U.S. Food & Drug Administration (FDA) on Wednesday endorsed a first-of-its-kind cancer treatment that makes use of patients’ revved-up immune cells to fight back the deadly disease.

Novartis to wait for 180 days before selling itsFDA-approved biosimilar Enbrel: US court

The US Food and Drug Administration on Tuesday approved Novartis’s Erelzi as a biosimilarof Amgen’s Enbrel, which is a drug for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic ar

New Heart Failure Drug Marketing Costs to Alleviate Novartis’ 2016 Profit

Novartis revealed on Tuesday that the company is boosting its expenditure on marketing a new heart failure drug called Entresto subsequent to disappointing initial sales of the medicine. This increase in expenditure might have a dampening impact on the profit of Novartis in 2016.

Novartis Drug for Heart Failure fails to Seek Approval from FDA Panel

Novartis AG's heart failure drug, serelaxin, failed to seek support from a United States Food and Drug Administration panel. Due to lack of evidence of the drug to benefit heart patients, the FDA panelists voted unanimously against the drug. However, a final decision is still awaited till May 17.